Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZL-IRIAN: Anlotinib + Irinotecan +/- Penpulimab in 2L mCRC
NCT05229003Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Started Mar 2022; status: recruiting.
02
Drugs
anlotinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05229003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229003.